Vicore to host webcast with updated AIR trial results after presentation at the ATS congress
Webcast to be held on: May 26, 2023 at 08:00 EST/14:00 CET
Stockholm, May 17, 2023 – Vicore Pharma Holding AB (STO:VICO) (“Vicore”), unlocking the potential of a new class of drugs to stop disease progression and restore function, will hold a webcast including a Q&A session to present interim results from the phase 2a trial AIR, which evaluates treatment with C21 in patients with idiopathic pulmonary fibrosis (IPF), on May 26 2023 at 08:00 EST/14:00 CET. C21 is a first-in-class orally administered angiotensin II type 2 receptor agonist (ATRAG) in development for the treatment of IPF.